

20th OCTOBER 2008

TRADE UPDATE FOR 9 MONTHS OF 2008 (UNAUDITED)

October 20, 2008, MOSCOW – OJSC Pharmacy Chain 36.6 [RTS:APTK; MICEX:RU14APTK1007] the leading Russian pharmaceutical retailer announces unaudited sales and operational results according to the management accounts.

GROUP SALES¹:

- Y-o-Y in 9M 2008 Group's consolidated sales increased by 38,6% and reached US\$ 820,7 million.
- Sales of the retail unit grew by 42,9% and reached US\$ 655,6 million.
- Sales of the production unit Veropharm grew by 38.2% and reached US\$128,4
- Sales of Early Learning Center grew by 110.5% to \$3.3 million
- Other non-core businesses declined by 14,5% as the Company no longer consolidates the operation of European Medical Center.

<i>USD mln</i>	Consolidated	Retail	Veropharm	ELC	Other
9M 2008	820,7	655,6	128,4	3,3	33,1
9M 2007	592,0	458,8	92,9	1,6	38,7
<i>Change y-o-y</i>	<i>38,6%</i>	<i>42,9%</i>	<i>38,2%</i>	<i>110,5%</i>	<i>-14,5%</i>

RETAIL:

- As of the end of 9M 2008 Pharmacy Chain 36.6 operates 1168 stores in 29 regions of Russia.
- During Q3 2008 29 stores were opened organically and 52 were closed; 5 stores rebranded and 2 reformatted.
- As of the end of 9M 2008 Pharmacy Chain 36.6 operates 10 ELC stores, 13 stand-alone optical outlets and 22 additional optical departments within pharmacies.
- At the end of September, the Company successfully moved its National distribution center to a new location in Istrinsky region nearby Moscow and warehouse operations have been outsourced to a professional pharmaceutical logistics service provider, OOO «Pharmatsevticheskiye Terminaly». The center is now fully operational.

¹ Hereinafter – these financial indicators may vary from the consolidated financial reporting prepared in accordance with IFRS.

9M 2008

Business Unit²	No. of pharmacies	Share of Sales	Ave. retail space per pharmacy, sq.m.
1. Moscow-Central	395	43,3%	73.7
<i>Northwest</i>	27	2,73%	67.7
2. South Urals	264	17,4%	56.6
3. South	206	16,5%	50.0
4. Volga	130	8,9%	62.2
5. North Urals	105	9,5%	54.0
6. Siberia	68	4,4%	53.1
Company Total:	1168	100%	61.4

OPERATIONAL DATA FOR THE RETAIL UNIT

- During 9 months of 2008, 77.4 million purchases were made in Pharmacy Chain 36.6, which is 21% higher than in comparable period of 2007.
- In Q3 2008 average check across the network reached US\$ 8.36, in Moscow US\$ 10.09 , an increase over the comparable period of the previous year 15.2% and 13.7% respectively.
- Average sales floor size at the end of Q3 is 61.4 sq meters, a decrease of 0.5% versus 2007.

LIKE-FOR-LIKE SALES IN COMPARABLE STORES³

As of the end of Q3 2008 the Company operates 535 comparable stores representing 55% of sales and 51% of traffic in the retail unit.

The L-F-L sales growth in these stores in 9M 2008 reached 17% as compared to 9M 2007 while the traffic decreased by 7%:

Business unit	Number of comparable stores	L-F-L sales growth USD	Average check growth, USD
1. Moscow-Central	195	19%	20%
<i>Northwest</i>	19	42%	38%
2. South Urals	168	13%	30%
3. South	58	15%	30%
4. Volga	81	14%	28%
5. North Urals	1	11%	35%
6. Siberia	13	25%	40%
Total:	535	17%	27%

#

² Due to organizational changes Northwest is now managed by Moscow-Central. In addition, Urals is broken into two units: North Urals and South Urals.

³ Comparable stores are defined as stores:

- Opened or acquired 24 months from the current reporting period, and
- Neither rebranded nor reformatted or somehow significantly changed during last 24 months, and
- Not closed in the current reporting period.

For further information please refer to:

Maxim Arkhipov

Director, Corporate finance and investor relations

arkhipov@oao366.ru

tel. (+7495) 797 86 86 ext.1763

Maria Zhog

Director, Corporate communications

mzhog@oao366.ru

tel. (+7495) 797 86 86 ext.1534

Or to the web-site of the company:

www.pharmacychain366.ru

ir@oao366.ru

Notes to the editor:

Pharmacy Chain 36.6 is the first public national health and beauty retailer listed on the "B" list on the RTS (ticker: APTK) and off-list on the MICEX. The Company's market capitalization as of October 17, 2008 totaled USD 85,5 million (according to RTS). Pharmacy Chain 36.6 operates more than 1100 stores in 29 regions and 90 cities in Russia.

OAO Veropharm, the company's generics subsidiary, is one of Russia's top five pharmaceutical manufacturers (according to Pharmexpert research). Veropharm's shares are traded in the "B" list on the RTS (ticker: VRPH) and off-list on MICEX (ticker: VRFM). OAO Veropharm's market capitalization as of October 17, 2008 was USD 250 million (according to RTS).

ZAO Apteki 36.6 is one of the founding members of the Russian Association of Pharmacy Chains (RAPC). Pharmacy Chain 36.6 and its subsidiaries employ over 11,000 people.

THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION AND IS NOT AN OFFER TO SELL OR AN INVITATION TO MAKE OFFERS TO PURCHASE ANY SECURITIES IN THE RUSSIAN FEDERATION.

NOT FOR RELEASE DIRECTLY OR INDIRECTLY IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

This document should not be considered a public offering of securities in the United States. Any securities referred to herein have not been and will not be registered under the US Securities Act of 1933 as amended (the "Securities Act") and may not be offered or sold in the United States or to US persons.

This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom and (b) persons in the United Kingdom who have (i) professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (the "Order") or (ii) high net worth companies and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49(2) of the Order (all such persons specified in clauses (a) and (b) and together being referred to as "relevant persons"). Any securities referred to in this press release and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.